AAP
TMCI icon

Arax Advisory Partners’s Treace Medical Concepts TMCI Stock Holding History

Arax Advisory Partners’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17
Closed -$42 – 4318
2025
Q4 		$42 Sell
17
-3,547
-100% -$15.4K ﹤0.01% 3949
2025
Q3 		$23.9K Buy
+3,564
New +$23.3K ﹤0.01% 2183
2025
Q2 		– Sell
-106
Closed -$890 – 3191
2025
Q1 		$890 Hold
106
– – ﹤0.01% 2339
2024
Q4 		$789 Buy
+106
New +$709 ﹤0.01% 2221

Other funds holding TMCI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CBU
CIBC Bancorp USA Chicago, Illinois $74.4B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arax Advisory Partners's TMCI Position: Q1 2026 in Review

Arax Advisory Partners sold out of Treace Medical Concepts (TMCI) in Q1 2026, closing a stake of 17 shares — an estimated $42 sold.

Arax Advisory Partners first reported a position in TMCI in Q4 2024 and held it in 4 quarters. The position peaked at $23.9K in Q3 2025. 118 funds tracked by Wall St. Rank hold TMCI as of Q1 2026.

  • Arax Advisory Partners reported no remaining Treace Medical Concepts position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 17 Treace Medical Concepts shares in Q1 2026, an estimated $42.
  • Arax Advisory Partners first reported a position in Treace Medical Concepts in Q4 2024 and held it in 4 quarters.
  • Arax Advisory Partners's Treace Medical Concepts position peaked at $23.9K in Q3 2025.
  • 118 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.